Clinical trial
The Efficacy of Tislelizumab Combined With S-1 in Patients With Residual Primary Lesions and Node-Negative Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Followed by Curative Resection: A Phase II, Multicenter Trial
NCT06354140 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy of Tislelizumab Combined With S-1 in Patients With Residual Primary Lesions and Node-Negative Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Followed by Curative Resection: A Phase II, Multicenter Trial
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 7, 2024
- Completion date
- May 30, 2028
- Enrollment
- 45 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.